United Therapeutics (FRA:UTH) Institutional Ownership : 59.31% (As of Apr. 28, 2024)

View and export this data going back to . Start your Free Trial

What is United Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, United Therapeutics's institutional ownership is 59.31%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, United Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, United Therapeutics's Float Percentage Of Total Shares Outstanding is 88.27%.

United Therapeutics Institutional Ownership Historical Data

The historical data trend for United Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Institutional Ownership Chart

United Therapeutics Historical Data

The historical data trend for United Therapeutics can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	65.74	65.25	65.15	64.52	61.39	61.72	60.56	59.89	58.58	59.31

United Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

United Therapeutics (FRA:UTH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (FRA:UTH) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

UTHR:USA UTH:Germany

Address

1040 Spring Street, Silver Spring, MD, USA, 20910

Website

https://www.unither.com

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

United Therapeutics (FRA:UTH) Headlines

No Headlines